-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Neutral on Pacific Biosciences, Raises Price Target to $3

Benzinga·11/05/2026 16:56:57
Listen to the news
Piper Sandler analyst David Westenberg reiterates Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $2 to $3.